Size : 1g
Phone : +1 850 650 7790
Synonyms: D-Galactopyranose, D-(+)-Galactose, Alpha-D-galactose
| Description | D-Galactose is a naturally occurring hexose and a C-4 epimer of glucose. It can combine with glucose to form lactose and is commonly used to establish animal models of aging. |
| In vitro | Galactose is important for the survival and virulence of bacteria. Galactose is utilized by the Leloir pathway in Escherichia coli. Two anomers of d-galactose are used for different purposes, α-d-galactose as a carbon source and β-d-galactose for induction of UDP-galactose synthesis for biosynthetic glycosylation[1]. |
| In vivo | Chronic D-galactose exposure induces neurodegeneration by enhancing caspase-mediated apoptosis and inhibiting neurogenesis and neuron migration in mice, as well as increasing oxidative damage. Moreover, D-galactose-induced toxicity in mice is a useful model for studying the mechanisms of neurodegeneration and neuroprotective drugs and agents[2]. D-galactose given by oral route leads to cognitive impairments in rats which are accompanied by oxidative damage. Cognitive impairments is observed in the open-field test in the 4th and 6th weeks after d-gal administration, as well as an impairment in spatial memory in the radial maze test after the 6th week of d-gal administration[3]. |
| Synonyms | D-Galactopyranose, D-(+)-Galactose, Alpha-D-galactose |
| Disease Modeling Protocol | Aging model
*Precautions： *References：Chang K,et,al. Galactose ingestion increases vascular permeability and collagen solubility in normal male rats. J Clin Invest. 1987 Feb;79(2):367-73. |
| Molecular Weight | 180.16 |
| Formula | C6H12O6 |
| Cas No. | 59-23-4 |
| Smiles | [C@@H]([C@@H]([C@H](C=O)O)O)([C@@H](CO)O)O |
| Relative Density. | 1.5 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 66 mg/mL (366.34 mM), Sonication is recommended. DMSO: 86.6 mg/mL (480.68 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (18.32 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
